Swiss medical authority approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) combination as 1L maintenance therapy for ES-SCLC December 2, 2025
FDA grants accelerated approval to HYRNUO™ (sevabertinib) for patients with previously treated advanced HER2-mutant NSCLC November 24, 2025
European Commission Approves Subcutaneous Administration of KEYTRUDA® for All Adult Indications Approved in the European Union November 24, 2025
FDA Approves KEYTRUDA® and KEYTRUDA QLEX™ (berahyaluronidase alfa-pmph formulation), Each with Padcev®, as Perioperative Treatment for Adults with Cisplatin-Ineligible MIBC November 24, 2025
FDA approves EPKINLY® (epcoritamab-bysp), Rituximab and Lenalidomide combo for the Treatment of R/R Follicular Lymphoma November 24, 2025
DARZALEX FASPRO® approved by FDA for patients with high-risk smoldering multiple myeloma November 10, 2025
EC Approves KEYTRUDA as Part of Treatment Regimen for Adults with Resectable LA-HNSCC Expressing PD-L1 November 4, 2025
FDA Approves Revuforj® (revumenib) in Adult & Pediatric Patients with R/R NPM1 Mutated AML October 29, 2025
NMPA approves trastuzumab botidotin (A166) for patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2 therapy October 18, 2025
Libtayo® (cemiplimab-rwlc) Approved in US for Adjuvant Treatment of CSCC with a High Risk of Recurrence After Surgery and Radiation October 15, 2025
FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer September 30, 2025
FDA Approves SC KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection Across Most Solid Tumor Indications for KEYTRUDA September 23, 2025
European Commission Approves VORANIGO® (vorasidenib) for Grade 2 IDH-Mutant Glioma September 23, 2025
HERNEXEOS® approved in China for previously treated patients with HER2-mutant advanced NSCLC September 3, 2025
ENHERTU® Approved in Japan for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy September 3, 2025
Hong Kong Department of Health approves TIVDAK (tisotumab vedotin-tftv) in Hong Kong for patients with recurrent or metastatic cervical cancer September 3, 2025
DATROWAY® Approved in China for Patients with Previously Treated Metastatic HR+ve, HER2-neg Breast Cancer September 3, 2025
FDA approved CAMCEVI ETM long-acting injectable formulation for advanced prostate cancer September 3, 2025
